31,158 Shares in ProQR Therapeutics (NASDAQ:PRQR) Bought by Virtu Financial LLC

Virtu Financial LLC bought a new stake in ProQR Therapeutics (NASDAQ:PRQR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 31,158 shares of the biopharmaceutical company’s stock, valued at approximately $83,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRQR. BNP Paribas Financial Markets boosted its position in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 7,300 shares in the last quarter. Ballentine Partners LLC bought a new position in ProQR Therapeutics during the fourth quarter worth about $61,000. M&T Bank Corp acquired a new position in ProQR Therapeutics in the fourth quarter valued at about $330,000. Raymond James Financial Inc. bought a new stake in shares of ProQR Therapeutics in the fourth quarter worth about $260,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $77,000. Institutional investors own 32.65% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on PRQR shares. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th. HC Wainwright increased their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective on the stock. Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a report on Monday, March 10th. Finally, JMP Securities restated a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $1.33 on Tuesday. The business has a 50-day moving average of $2.06 and a 200-day moving average of $2.60. The stock has a market capitalization of $139.93 million, a price-to-earnings ratio of -4.16 and a beta of 0.24. ProQR Therapeutics has a fifty-two week low of $1.29 and a fifty-two week high of $4.62.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).